AveXis (NASDAQ:AVXS)‘s stock had its “buy” rating reaffirmed by analysts at BMO Capital Markets in a research note issued on Thursday. They currently have a $150.00 target price on the stock. BMO Capital Markets’ price objective indicates a potential upside of 38.57% from the company’s current price.

A number of other equities analysts have also recently weighed in on AVXS. Canaccord Genuity set a $110.00 price objective on shares of AveXis and gave the stock a “hold” rating in a research report on Friday, January 5th. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Citigroup upped their price objective on shares of AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a research report on Monday, October 2nd. Morgan Stanley set a $120.00 price objective on shares of AveXis and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Chardan Capital restated a “buy” rating and set a $135.00 price objective on shares of AveXis in a research report on Friday, January 5th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $113.89.

AveXis (NASDAQ:AVXS) traded down $1.92 during trading hours on Thursday, reaching $108.25. 777,156 shares of the company’s stock were exchanged, compared to its average volume of 547,921. AveXis has a 52 week low of $50.56 and a 52 week high of $119.00.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same period in the prior year, the business posted ($0.87) EPS. equities analysts predict that AveXis will post -6.23 EPS for the current fiscal year.

In related news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $101.26, for a total value of $180,242.80. Following the completion of the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $180,242.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP James J. Litalien sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $106.52, for a total transaction of $532,600.00. The disclosure for this sale can be found here. Insiders sold 57,340 shares of company stock valued at $5,851,445 in the last three months. 18.60% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in AVXS. Janus Henderson Group PLC purchased a new stake in shares of AveXis in the second quarter valued at about $55,439,000. BlackRock Inc. grew its holdings in shares of AveXis by 34.7% in the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after purchasing an additional 592,843 shares during the period. FMR LLC grew its holdings in shares of AveXis by 13.1% in the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after purchasing an additional 544,475 shares during the period. State Street Corp grew its holdings in shares of AveXis by 104.2% in the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after purchasing an additional 510,189 shares during the period. Finally, Westfield Capital Management Co. LP purchased a new stake in shares of AveXis in the third quarter valued at about $39,563,000. 92.88% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “AveXis (AVXS) Receives “Buy” Rating from BMO Capital Markets” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/20/avexis-avxs-receives-buy-rating-from-bmo-capital-markets.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.